Abstract

DEXTROMETHORPHAN HYDROBROMIDE CONTAINING MEDICATED LOLLIPOP

Ashwini Mahajan*, Manasi Sangave, Kalyani Pagare and Dr. Avinash B. Darekar

ABSTRACT

Lollipops represent an emerging and effective platform for oral drug delivery, particularly suited for achieving localized therapeutic effects in the oral cavity and pharyngeal region. These dosage forms are typically manufactured through a process involving the melting and subsequent solidification of a sucrose or sugar-based carrier matrix, into which the active pharmaceutical ingredient is incorporated. This delivery route offers several pharmacokinetic and therapeutic advantages, including enhanced bioavailability, dose reduction, bypassing of gastrointestinal absorption, and avoidance of first-pass hepatic metabolism. Such characteristics render medicated lollipops particularly advantageous in improving patient adherence, especially among populations with swallowing difficulties. The etymology of the term lollipop traces back to the 18th century, with Englishlexicographer Francis Grose first recording it in 1796. The term is believed to originate from the word “lolly,” meaning “tongue,” and “pop,” implying a light strike or slap. Swallowing solid oral dosage forms, such as tablets or capsules, often poses challenges for various patient demographics, particularly the pediatric and geriatric populations. In addition, the lack of access to potable water can further complicate administration. These issues contribute to reduced patient compliance and therapeutic efficacy. To address such limitations, medicated lollipops have been developed as a palatable, taste-masked, and user-friendly alternative.

Keywords: Medicated lollipop, dysphagia, heating and congealing method, loli phaba.